Program
SKB107
A development code. Also written as “SKB107 for injection”.
Its studies are led by Sichuan Kelun Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical | 11 open or running | phase 1since Jun 30, 2025 | Jun 30, 2025 | Oct 1, 2027phase 1 · NCT07087197 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2025First study: phase 1 study in Metastatic Solid TumorsFirst studyNCT07087197 · 90 planned · China
Ahead
- Oct 1, 2027Primary completion: phase 1 study in Metastatic Solid TumorsNCT07087197
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07087197Metastatic Solid Tumors · China | 1 | Recruiting | Oct 1, 2027 | 90 |
How it is read
Names in the registry
- “SKB107 for injection”, 1 entry
Codes read as this program: SKB107.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.